Tailor-made T-lymphocyte receptor library
Chimeric Antigen Receptor T-cell therapy (CAR-T) therapy is one of the most effective Immunotherapy methods for malignant tumors. Chimeric antigen receptor (CAR) is the core parts of the CAR – T, which is an engineered T-cell receptor (TCR) construct by fusion tumor associate antigen-specific ScFv antibody with an extracellular hinge area, a transmembrane domain (TMD) and an intracellular T-cell signaling domain. All these processes lead to a CAR capable of specific tumor cell binding and activating T-cells to achieve cytotoxic potential. CAR-Ts Identify tumor cells in a HLA independent manner, which is different from natural T cell surface receptors that identify a wider range of targets.
Based on Gegen CHO cell antibody screening platform, ScFv and VHH antibodies against natural conformation of tumor association antigens expressed on CHO surface are isolated from our human antibody library. Antibody genes are inserted into CAR structures for CAR-T therapy. T cell chimeric receptors screened by antigen expression eukaryotic cell is maximum similar to their natural conformation in vivo environment and is most suitable for antibody drug development and immunotherapy.